BR0313534A - Antagonistas de integrinade ácido carboxìlico de piperidinoìla - Google Patents

Antagonistas de integrinade ácido carboxìlico de piperidinoìla

Info

Publication number
BR0313534A
BR0313534A BR0313534-9A BR0313534A BR0313534A BR 0313534 A BR0313534 A BR 0313534A BR 0313534 A BR0313534 A BR 0313534A BR 0313534 A BR0313534 A BR 0313534A
Authority
BR
Brazil
Prior art keywords
carboxylic acid
piperidineyl
integrin antagonists
acid integrin
antagonists
Prior art date
Application number
BR0313534-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Bart De Corte
William A Kinney
Bruce E Maryanoff
Shyamali Ghosh
Livia Brunner
Li Liu
Robert A Galemmo Jr
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0313534A publication Critical patent/BR0313534A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0313534-9A 2002-08-16 2003-08-15 Antagonistas de integrinade ácido carboxìlico de piperidinoìla BR0313534A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40423902P 2002-08-16 2002-08-16
PCT/US2003/025782 WO2004020435A1 (en) 2002-08-16 2003-08-15 Piperidinyl compounds that selectively bind integrins

Publications (1)

Publication Number Publication Date
BR0313534A true BR0313534A (pt) 2005-07-12

Family

ID=31978252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313534-9A BR0313534A (pt) 2002-08-16 2003-08-15 Antagonistas de integrinade ácido carboxìlico de piperidinoìla

Country Status (24)

Country Link
US (1) US20040077684A1 (enExample)
EP (1) EP1539739B1 (enExample)
JP (1) JP4554364B2 (enExample)
KR (1) KR20050031464A (enExample)
CN (1) CN100506815C (enExample)
AR (1) AR041010A1 (enExample)
AT (1) ATE489378T1 (enExample)
AU (2) AU2003259891A1 (enExample)
BR (1) BR0313534A (enExample)
CA (1) CA2496127C (enExample)
CR (1) CR7692A (enExample)
CY (1) CY1111194T1 (enExample)
DE (1) DE60335118D1 (enExample)
DK (1) DK1539739T3 (enExample)
ES (1) ES2355139T3 (enExample)
IL (1) IL166534A (enExample)
MX (1) MXPA05001859A (enExample)
NO (1) NO332036B1 (enExample)
PL (1) PL219749B1 (enExample)
PT (1) PT1539739E (enExample)
RU (1) RU2333210C2 (enExample)
SI (1) SI1539739T1 (enExample)
UA (1) UA83467C2 (enExample)
WO (1) WO2004020435A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US7351711B2 (en) 2003-07-31 2008-04-01 Janssen Pharmaceutical, N.V. Tricyclic indanyls as integrin inhibitors
HRP20130782T1 (en) 2004-04-02 2013-09-30 The Regents Of The University Of California, Office Of Technology Transfer Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
BRPI0519739A2 (pt) * 2004-12-30 2009-03-10 Cinv Ag combinaÇço compreendendo um agente fornecendo um sinal, um material de implante e uma droga
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
US8372399B2 (en) * 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
CN101821256A (zh) * 2007-08-02 2010-09-01 瑞蔻达蒂爱尔兰有限公司 作为mGlu5拮抗剂的新型杂环化合物
US8680278B2 (en) * 2007-10-30 2014-03-25 Janssen Pharmaceutica Nv Enantioselective process for preparing a substituted alkanoic acid
EP2217238B1 (en) * 2007-11-08 2014-03-12 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2456460A4 (en) 2009-07-24 2013-02-20 Univ California METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN
FI3929196T3 (fi) 2013-09-24 2023-10-02 Fujifilm Corp Typpeä sisältävän yhdisteen tai sen suolan tai niiden metallikompleksin farmaseuttinen koostumus
JP2019530678A (ja) 2016-09-18 2019-10-24 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｙａｐ１のｏｃｔ４との相互作用を標的とするｙａｐ１阻害剤
BR112019009245A2 (pt) * 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
JP7220653B2 (ja) * 2016-11-08 2023-02-10 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロールアミド
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
CN116283977A (zh) 2017-02-28 2023-06-23 莫菲克医疗股份有限公司 αvβ6整合蛋白的抑制剂
EA202092174A1 (ru) 2018-03-14 2021-01-15 Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют, Инк. Ингибиторы yap1, которые нацелены на взаимодействие yap1 с oct4
SG11202101913PA (en) 2018-08-29 2021-03-30 Morphic Therapeutic Inc INHIBITING aV ß6 INTEGRIN
CN120282949A (zh) * 2023-09-28 2025-07-08 云合智药（苏州）生物科技有限公司 靶向整合素的化合物及其在RNAi剂中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (enExample) * 1977-06-03 1981-03-07 Pfizer
CA2131528C (en) * 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5700801A (en) * 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
DE69830806T2 (de) * 1997-12-17 2006-04-27 Merck & Co., Inc. Integrinrezeptor antagonisten
US6211191B1 (en) * 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
WO2000000481A1 (en) * 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device

Also Published As

Publication number Publication date
CN1688572A (zh) 2005-10-26
SI1539739T1 (sl) 2011-04-29
IL166534A (en) 2012-05-31
EP1539739B1 (en) 2010-11-24
CA2496127C (en) 2012-05-29
AU2010236002B2 (en) 2012-05-03
KR20050031464A (ko) 2005-04-06
PL219749B1 (pl) 2015-07-31
IL166534A0 (en) 2006-01-15
CR7692A (es) 2009-01-14
CN100506815C (zh) 2009-07-01
DE60335118D1 (de) 2011-01-05
PL375562A1 (en) 2005-11-28
CY1111194T1 (el) 2015-06-11
ATE489378T1 (de) 2010-12-15
AR041010A1 (es) 2005-04-27
CA2496127A1 (en) 2005-02-16
JP4554364B2 (ja) 2010-09-29
RU2333210C2 (ru) 2008-09-10
UA83467C2 (uk) 2008-07-25
ES2355139T3 (es) 2011-03-23
MXPA05001859A (es) 2005-06-03
AU2010236002A1 (en) 2010-11-11
JP2005539049A (ja) 2005-12-22
EP1539739A1 (en) 2005-06-15
AU2003259891A1 (en) 2004-03-19
WO2004020435A1 (en) 2004-03-11
DK1539739T3 (da) 2011-03-07
PT1539739E (pt) 2011-01-05
NO20051273L (no) 2005-05-10
NO332036B1 (no) 2012-06-04
RU2005104115A (ru) 2005-08-27
US20040077684A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
BR0313534A (pt) Antagonistas de integrinade ácido carboxìlico de piperidinoìla
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
FR19C1014I1 (fr) Utilisation de derives de benzimidazole alkyles n3 en tant qu'inhibiteurs de mek
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
DE69838678D1 (de) ZYKLISCHE ANTAGONISTEN DER C5a REZEPTOREN SOWIE DER G-PROTEIN GEKOPPELTEN REZEPTOREN
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
ATE333644T1 (de) Vorrichtung zur bestimmung der feinheit von mineralfasern
NI200900100A (es) Antagonistas de receptor de orexina de diazepan sustituido
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
BR0002518A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
EA200970350A1 (ru) Антагонисты ccr2 для лечения фиброза
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
DE602004029241D1 (de) Der chemokin-rezeptor-aktivität
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
ATE306272T1 (de) Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
BRPI0407913A (pt) antagonistas receptores de ccr-3
BRPI0408529A (pt) derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios
ATE366572T1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2475 DE 12-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.